Viatris Inc VTRS

NASDAQ US Health Care Pharmaceuticals
$17.56 ▼ -1.13% ($-0.20)
Index member: S&P 500
⬇️ Below Yest. Low 📅 Earnings This Week
Open $17.65
Prev Close $17.76
Day Range $17.38 – $17.69
52W Range $8.63 – $18.07
Market Cap $20.23B
Beta 0.90
Div Yield 2.70%
EPS (TTM) $-0.26

📋 Company Profile

IndustryPharmaceuticals
SectorHealth Care
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date1973-02-01
Shares Out.1,164,550,000
Websiteviatris.com/en ↗
Phone13026587581
Employees30,000
Revenue$3.52B
Gross Profit$1.16B
Net Income$176.4M
Free Cash Flow$1.79B
Total Assets$36.83B
Total Liabilities$22.18B
Equity$14.66B
About Viatris Inc

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Inc is a publicly traded company under the ticker symbol VTRS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

📊 Analyst Ratings

17 analysts (2026-07-01)

Strong Buy 4
Buy 7
Hold 5
Sell 1

📰 Latest News for VTRS

👥 Related Stocks